139 related articles for article (PubMed ID: 620951)
1. Phase II evaluation of VP-16-213 (NSC-141540) in patients with advanced ovarian carcinoma resistant to alkylating agents.
Edmonson JH; Decker DG; Malkasian GD; Webb MJ; Jorgensen EO
Gynecol Oncol; 1978 Feb; 6(1):7-9. PubMed ID: 620951
[No Abstract] [Full Text] [Related]
2. Phase II clinical trial of VP-16-213 in ovarian cancer.
Maskens AP; Armand JP; Lacave AJ; De Jager RL; Hansen HH; Wolff JP
Cancer Treat Rep; 1981; 65(3-4):329-30. PubMed ID: 7016320
[No Abstract] [Full Text] [Related]
3. Phase II trial of VP-16-213 in advanced ovarian carcinoma.
Hillcoat BL; Campbell JJ; Pepperell R; Quinn MA; Bishop JF; Day A
Gynecol Oncol; 1985 Oct; 22(2):162-6. PubMed ID: 4054715
[TBL] [Abstract][Full Text] [Related]
4. A combination of cyclophosphamide, methotrexate, vincristine and VP 16-213 (NSC 141 540) in the treatment of bronchogenic carcinoma.
Cavalli F; Hasler E; Ryssel HJ; Sonntag RW; Brunner KW
Tumori; 1977; 63(2):169-73. PubMed ID: 898287
[TBL] [Abstract][Full Text] [Related]
5. Phase II evaluation of cytembena (NSC-104801) in patients with advanced ovarian carcinoma resistant to alkylating agents: brief communication.
Edmonson JH; Decker DG; Malkasian GD; Webb MJ; Jorgensen EO
J Natl Cancer Inst; 1977 Dec; 59(6):1619-20. PubMed ID: 579188
[TBL] [Abstract][Full Text] [Related]
6. [Phase II study of etoposide (VP-16-213) in genitourinary tumors. VP-16-213 Genitourinary Study Group].
Suzuki K
Gan To Kagaku Ryoho; 1986 Sep; 13(9):2772-9. PubMed ID: 3753024
[TBL] [Abstract][Full Text] [Related]
7. Phase II trial of VP-16-213 in the treatment of advanced squamous cell carcinoma of the cervix and adenocarcinoma of the ovary: a Gynecologic Oncology Group Study.
Slayton RE; Creasman WT; Petty W; Bundy B; Blessing JA
Cancer Treat Rep; 1979; 63(11-12):2089-92. PubMed ID: 526942
[No Abstract] [Full Text] [Related]
8. Oral VP-16-213 in transitional cell carcinoma of the bladder: a phase II study.
Panduro J; Hansen M; Hansen HH
Cancer Treat Rep; 1981; 65(7-8):703-4. PubMed ID: 7248987
[No Abstract] [Full Text] [Related]
9. Multicenter Phase II trial of etoposide in refractory small cell lung cancer.
Issell BF; Einhorn LH; Comis RL; Lawson RD; Baker LH; Harvey HA; Lanzotti VA; Wampler GL; Daniels JR; Anderson PN
Cancer Treat Rep; 1985 Jan; 69(1):127-8. PubMed ID: 2981617
[No Abstract] [Full Text] [Related]
10. [A phase II study of etoposide (VP-16) injection in primary lung cancer by cooperative study group].
Kado M; Oshima S; Matsui Y; Shimokata K; Hara K; Kanda T; Shima K; Takenaka S
Gan To Kagaku Ryoho; 1986 Jan; 13(1):116-21. PubMed ID: 3002282
[TBL] [Abstract][Full Text] [Related]
11. [A phase II study of intravenous VP-16-213 in small cell and non-small cell carcinoma of the lung].
Konno K; Nagahama F; Nakai Y; Nakabayashi T; Hiraga Y; Takebe K; Tamura M; Oizumi K; Sato M; Ito T
Gan To Kagaku Ryoho; 1986 Apr; 13(4 Pt 1):931-7. PubMed ID: 3008671
[TBL] [Abstract][Full Text] [Related]
12. [Collaborative phase II study of etoposide (NK-171). Urological Cooperative Study Group of etoposide (NK-171)].
Gan No Rinsho; 1985 Jul; 31(8):944-52. PubMed ID: 4040986
[TBL] [Abstract][Full Text] [Related]
13. Oral etoposide in gestational trophoblastic disease.
Wong LC; Choo YC; Ma HK
Cancer Treat Rep; 1984 May; 68(5):775-7. PubMed ID: 6327035
[TBL] [Abstract][Full Text] [Related]
14. Phase II study of etoposide (VP-16) in the treatment of advanced head and neck cancer.
Grunberg SM; Felman IE; Gala KV; Johnson KB; Owens JC
Am J Clin Oncol; 1985 Oct; 8(5):393-5. PubMed ID: 4061373
[TBL] [Abstract][Full Text] [Related]
15. Clinical trial of the oral form of a new podophyllotoxin derivative, VP-16-213 (NSC-141540), in patients with advanced neoplastic disease.
Nissen NI; Hansen HH; Pedersen H; Stroyer I; Dombernowsky P; Hessellund M
Cancer Chemother Rep; 1975; 59(5):1027-9. PubMed ID: 1106845
[No Abstract] [Full Text] [Related]
16. [A phase II clinical trial of oral VP 16-213 in advanced non-Hodgkin's lymphoma].
Nakada H; Ogawa M; Ingaki J; Horikoshi N; Inoue K; Usui N; Adachi K; Tada A; Yamazaki H; Mukaiyama T
Gan To Kagaku Ryoho; 1984 Aug; 11(8):1644-8. PubMed ID: 6476837
[TBL] [Abstract][Full Text] [Related]
17. [Phase II study of NK 171 (etoposide) on malignant lymphomas and acute leukemia. A cooperative study group on NK 171 in hematological malignancies].
Kimura K; Yamada K; Yoshida T
Gan To Kagaku Ryoho; 1986 Mar; 13(3 Pt 1):496-501. PubMed ID: 3954373
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic trials with VP-16-213 and VM-26: active agents in small cell lung cancer, non-Hodgkin's lymphomas, and other malignancies.
Radice PA; Bunn PA; Ihde DC
Cancer Treat Rep; 1979 Aug; 63(8):1231-9. PubMed ID: 225026
[No Abstract] [Full Text] [Related]
19. [A phase II study of NK171 (etoposide)].
Kimura K; Niitani H
Gan To Kagaku Ryoho; 1985 Oct; 12(10):2011-7. PubMed ID: 2996442
[TBL] [Abstract][Full Text] [Related]
20. [Phase II study of etoposide (NK 171) in advanced hematological malignancies].
Yoshida T; Nakanishi J; Ito K; Kobayashi S; Ohtake S; Nakamura S; Hattori K
Gan To Kagaku Ryoho; 1984 Aug; 11(8):1579-84. PubMed ID: 6476835
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]